Reverse Transcriptase-Polymerase Chain Reaction to Evaluate Human Cytomegalovirus Lytic Gene Expression
Tóm tắt
This paper describes the development of four Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assays devised to evaluate lytic (UL123, immediate-early; UL54, early; UL65, late; and UL99, true late) human cytomegalovirus (HCMV) transcripts. Subsequently, the assays have been validated evaluating the HCMV lytic gene expression in 28 samples (peripheral blood leukocytes, PBLs) from 14 renal transplant recipients. Although the assessment of HCMV transcriptional profile could be useful to evaluate viral reactivation state, further studies on dynamics of viral transcripts in different clinical settings are needed to determine the role of transcriptional profiling in virological monitoring and therapeutic management in immunocompromised patients.
Tài liệu tham khảo
Landolfo, S., Gariglio, M., Gribaudo, G., & Lembo, D. (2003). The human cytomegalovirus. Pharmacology and Therapeutics, 98, 269–297. doi:10.1016/S0163-7258(03)00034-2.
Reischig, T., Jindra, P., Svecova, M., Kormunda, S., Opatrny, K., Jr., & Treska, V. (2006). The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. Journal of Clinical Virology, 36, 146–151. doi:10.1016/j.jcv.2006.01.015.
Bergallo, M., Costa, C., Terlizzi, M. E., et al. (2008). Evaluation of two set of primers for detection of immediate early gene UL123 of human Cytomegalovirus (HCMV). Molecular Biotechnology, 38, 65–70. doi:10.1007/s12033-007-0074-5.
Bergallo, M., Costa, C., Tarallo,S., et al. (2006). Development of a quantitative-competitive PCR for quantification of HCMV load and comparison with antigenaemia, viraemia and pp67 RNA detection by NASBA. Panminerva Medica, 48, 119–127.
Cihlar, T., Fuller, M. D., & Cherrington, J. M. (1998). Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. Journal of Virology, 72, 5927–5936.
Larson, S., Soderberg-Naucler, C., Wang, F. Z., & Moller, E. (1998). Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion, 38, 271–278. doi:10.1046/j.1537-2995.1998.38398222871.x.
Saltzman, R. L., Quirk, M. R., & Jordan, M. C. (1992). High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. The Journal of Clinical Investigation, 90, 1832–1838. doi:10.1172/JCI116059.
Gozlan, J., Laporte, J. P., Lesage, S., et al. (1996). Monitoring of cytomegalovirus infection and disease in bone marrow recipients by reverse-transcription-PCR and blood and urine culture. Journal of Clinical Microbiology, 34, 2085–2088.
Meyer-Koenig, U., Romberg, I., Schneider, K., Weidmann, M., Kern, W. V., & Hufert, F. T. (2006). Diagnostic value of reverse transcription-PCR for detection of cytomegalovirus pp67 in samples from solid-organ transplant recipients. Journal of Clinical Microbiology, 44, 3394–3396. doi:10.1128/JCM.00493-06.
Lam, K. M. C., Oldenburg, N., Khan, M. A., et al. (1998). Significance of reverse transcription polymerase chain reaction in the detection of human cytomegalovirus gene transcripts in thoracic organ transplant recipients. The Journal of Heart and Lung Transplantation, 17, 555–565.
Meyer-Koning, U., Serr, A., von Laer, D., et al. (1995). Human cytomegalovirus immediate early and late transcripts in peripheral blood leukocytes: Diagnostic value in renal transplant recipients. The Journal of Infectious Diseases, 171, 705–709.
Nelson, P. N., Kawal, B. K., Boriskin, Y. S., et al. (1996). A polymerase chain reaction to detect a spliced late transcripts of human cytomegalovirus in the blood of bone marrow transplant recipients. Journal of Virological Methods, 56, 139–148. doi:10.1016/0166-0934(95)01900-6.
Oldenburg, N., Lan, K. M. C., Top, B., et al. (2000). Monitoring of CMV immediate early, early and late gene expression as prognostic markers of CMV disease in thoracic organ transplant recipients using NASBA. Transplantation, 70, 1209–1215. doi:10.1097/00007890-200010270-00015.
Boriskin, Y. S., Fuller, K., Powles, R. L., et al. (2002). Early detection of cytomegalovirus (CMV) infection in bone marrow transplant patients by reverse transcription-PCR for CMV spliced late gene UL21.5: A two site evaluation. Journal of Clinical Virology, 24, 13–23. doi:10.1016/S1386-6532(01)00209-8.
Allice, T., Enrietto, M., Pittaluga, F., et al. (2006). Quantitation of cytomegalovirus DNA by real-time polymerase chain reaction in peripheral blood specimens of patients with solid organ transplants: Comparison with end-point PCR and pp65 antigen test. Journal of Medical Virology, 78, 915–922. doi:10.1002/jmv.20641.
Lilleri, D., Gerna, G., Furione, M., et al. (2007). Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of pre-emptively treated children and young adults receiving haematopoietic stem cell transplantation as compared to qualitative pp65-antigenemia. Blood, 110, 2757–2760. doi:10.1182/blood-2007-03-080820.
Kim, D. J., Kim, S. J., Park, J., et al. (2007). Real-time PCR assay compared with antigenemia assay for detecting cytomegalovirus infection in kidney transplant recipients. Transplantation Proceedings, 39, 1458–1460. doi:10.1016/j.transproceed.2007.01.088.
Boivin, G., Goyette, N., Gilbert, C., Humar, A., & Covington, E. (2005). Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transplant Infectious Disease, 7, 166–170. doi:10.1111/j.1399-3062.2005.00112.x.
Nogueira, E., Ozaki, K. S., Tomiyama, H., Granato, C. F., Camara, N. O., & Pacheco-Silvia, A. (2006). The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients. International Immunopharmacology, 20, 2031–2037. doi:10.1016/j.intimp. 2006.07.022.
Scott, G. M., Isaacs, M. A., Zeng, F., Kesson, A. M., & Rawlinson, W. D. (2004). Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein Kinase) and UL54 (DNA polymerase) mutations. Journal of Medical Virology, 74, 85–93. doi:10.1002/jmv.20150.